Sphingosylphosphorylcholine acts in an anti-inflammatory manner in renal mesangial cells by reducing interleukin-1β-induced prostaglandin E 2 formation

Journal of Lipid Research

Volumn 48, Issue 9, 2007, Pages 1985-1996

  Xin, Cuiyan ^a   Ren, Shuyu ^a   Eberhardt, Wolfgang ^b   Pfeilschifter, Josef ^b   Huwiler, Andrea ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Connective tissue growth factor; Secretory phospholipase A2; Smad; Transforming growth factor 2

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; INTERLEUKIN 1BETA; MESSENGER RNA; PHOSPHOLIPASE A2; PHOSPHOTRANSFERASE INHIBITOR; PROSTAGLANDIN E2; SMAD PROTEIN; SPHINGOSYLPHOSPHORYLCHOLINE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; KIDNEY CELL; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; UPREGULATION;

ANIMALS; CELLS, CULTURED; DINOPROSTONE; INTERLEUKIN-1BETA; MESANGIAL CELLS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLCHOLINE; RATS; SIGNAL TRANSDUCTION; SMAD PROTEINS; SPHINGOSINE; TRANSFORMING GROWTH FACTOR BETA;

EID: 34548389809     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M700077-JLR200     Document Type: Article

References (69)

1. Meyer zu Heringdorf, D., H. M. Himmel, and K. H. Jakobs. 2002. Sphingosylphosphorylcholine - biological functions and mechanisms of action. Biochim. Biophys. Acta. 1582: 178-189.
2. Ishii, I., N. Fukushima, X. Ye, and J. Chun. 2004. Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 73: 321-354.
3. Zhu, K., L. M. Baudhuin, G. Hong, F. S. Williams, K. L. Cristina, J. H. Kabarowski, O. N. Witte, and Y. Xu. 2001. Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. J. Biol. Chem. 276: 41325-41335.
4. Hinckley, M., S. Vaccari, K. Horner, R. Chen, and M. Conti. 2005. The G-protein-coupled receptors GPR3 and GPR12 are involved in cAMP signaling and maintenance of meiotic arrest in rodent oocytes. Dev. Biol. 287: 249-261.
5. Xu, Y., K. Zhu, G. Hong, W. Wu, L. M. Baudhuin, Y. Xiao, and D. S. Damron. 2000. Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1. Nat. Cell Biol. 2: 261-267.
6. Kabarowski, J. H., K. Zhu, L. O. Le, O. N. Witte, and Y. Xu. 2001. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science. 293: 702-705.
7. Ludwig, M. G., M. Vanek, D. Guerini, J. A. Gasser, C. E. Jones, U. Junker, H. Hofstetter, R. M. Wolf, and K. Seuwen. 2003. Proton-sensing G-protein-coupled receptors. Nature. 425: 93-98.
8. Uhlenbrock, K., H. Gassenhuber, and E. Kostenis. 2002. Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors. Cell. Signal. 14: 941-953.
9. Bektas, M., L. S. Barak, P. S. Jolly, H. Liu, K. R. Lynch, E. Lacana, K. B. Shur, S. Milstien, and S. Spiegel. 2003. The G protein-coupled receptor GPR4 suppresses ERK activation in a ligand-independent manner. Biochemistry. 42: 12181-12191.
10. Czyborra, C., A. Bischoff, and M. C. Michel. 2006. Indomethacin differentiates the renal effects of sphingosine-1-phosphate and sphingosylphosphorylcholine. Naunyn Schmiedeb. Arch. Pharmacol. 373: 37-44.
11. Bischoff, A., P. Czyborra, C. Fetscher, D. Meyer zu Heringdorf, K. H. Jakobs, and M. C. Michel. 2000. Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro. Br. J. Pharmacol. 130: 1871-1877.
12. Bischoff, A., D. Meyer zu Heringdorf, K. H. Jakobs, and M. C. Michel. 2001. Lysosphingolipid receptor-mediated diuresis and natriuresis in anaesthetized rats. Br. J. Pharmacol. 132: 1925-1933.
13. 2+ signaling induced by sphingosylphosphorylcholine and sphingosine 1-phosphate via distinct mechanisms in rat glomerular mesangial cells. Kidney Int. 54: 1470-1483.
14. Pfeilschifter, J. 1989. Cross-talk between transmembrane signalling systems: a prerequisite for the delicate regulation of glomerular haemodynamics by mesangial cells. Eur. J. Clin. Invest. 19: 347-361.
15. Pfeilschifter, J. 1994. Mesangial cells orchestrate inflammation in the renal glomerulus. News Physiol. Sci. 9: 271-276.
16. Kashgarian, M., and R. B. Sterzel. 1992. The pathobiology of the mesangium. Kidney Int. 41: 524-529.
17. Leask, A., and D. J. Abraham. 2004. TGF-β signaling and the fibrotic response. FASEB J. 18: 816-827.
18. Kitamura, M., and T. S. Suto. 1997. TGF-β and glomerulonephritis: anti-inflammmatory versus prosclerotic actions. Nephrol. Dial. Transplant. 12: 669-679.
19. Agrotis, A., N. Kalinina, and A. Bobik. 2005. Transforming growth factor-β, cell signaling and cardiovascular disorders. Curr. Vasc. Pharmacol. 3: 55-61.
20. 2 in rat mesangial cells. Biochim. Biophys. Acta. 1355: 315-322.
21. Pfeilschifter, J., A. Kurtz, and C. Bauer. 1984. Activation of phospholipase C and prostaglandin synthesis by arginine vasopressin in cultures. Biochem. J. 223: 855-859.
22. Huwiler, A., S. Stabel, D. Fabbro, and J. Pfeilschifter. 1995. Platelet-derived growth factor and angiotensin II stimulate the mitogen-activated protein kinase cascade in renal mesangial cells: comparison of hypertrophic and hyperplastic agonists. Biochem. J. 305: 777-784.
23. 2 in human polymorphonuclear leukocytes. Biochim. Biophys. Acta. 879: 149-156.
24. 2 expression by peroxisome proliferator-activated receptor α activators in rat mesangial cells. J. Am. Soc. Nephrol. 13: 611-620.
25. Kahan, C., K. Seuwen, S. Meloche, and J. Pouyssegur. 1992. Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. Evidence for thrombin-induced signals different from phosphoinositide turnover and adenylylcyclase inhibition. J. Biol. Chem. 267: 13369-13375.
26. Desai, N. N., and S. Spiegel. 1991. Sphingosylphosphorylcholine is a remarkably potent mitogen for a variety of cell lines. Biochem. Biophys. Res. Commun. 181: 361-366.
27. Inman, G. J., F. J. Nicolas, J. F. Callahan, J. D. Harling, L. M. Gaster, A. D. Reith, N. J. Laping, and C. S. Hill. 2002. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62: 65-74.
28. Petry, C., A. Huwiler, W. Eberhardt, M. Kaszkin, and J. Pfeilschifter. 2005. Hypoxia increases group IIA phospholipase A(2) expression under inflammatory conditions in rat renal mesangial cells. J. Am. Soc. Nephrol. 16: 2897-2905.
29. Massague, J. 1998. TGF-beta signal transduction. Annu. Rev. Biochem. 67: 753-791.
30. Igarashi, A., H. Okochi, D. M. Bradham, and G. R. Grotenhorst. 1993. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol. Biol. Cell. 4: 637-645.
31. Riser, B. L., M. Denichilo, P. Cortes, C. Baker, J. M. Grondin, J. Lee, and R. G. Narins. 2000. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J. Am. Soc. Nephrol. 11: 25-38.
32. Leask, A., and D. J. Abraham. 2003. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem. Cell Biol. 81: 355-363.
33. Xin, C., S. Ren, B. Kleuser, S. Shabahang, W. Eberhardt, H. Radeke, M. Schäfer-Korting, J. Pfeilschifter, and A. Huwiler. 2004. Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-β-induced cell responses. J. Biol. Chem. 279: 35255-35262.
34. Xin, C., S. Ren, W. Eberhardt, J. Pfeilschifter, and A. Huwiler. 2006. The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Br. J. Pharmacol. 147: 164-174.
35. Brinkmann, V., M. D. Davies, C. E. Heise, R. Albert, S. Cottens, R. Hof, C. Bruns, E. Prieschl, T. Baumruker, P. Hiestand, et al. 2002. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277: 21453-21457.
36. Mandala, S., R. Hajdu, J. Bergstrom, E. Quackenbush, J. Xie, J. Milligan, R. Thornton, G. J. Shei, D. Card, C. Keohane, et al. 2002. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 296: 346-349.
37. Nofer, J. R., M. van der Giet, M. Tolle, I. Wolinska, K. von Wnuck Lipinski, H. A. Baba, U. J. Tietge, A. Godecke, I. Ishii, B. Kleuser, et al. 2004. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 113: 569-581.
38. Devi, D. A. 2001. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol. 22: 532-537.
39. Kim, J. H., J. H. Kim, W. K. Song, J. H. Kim, and J. S. Chun. 2000. Sphingosine 1-phosphate activates Erk-1/-2 by transactivating epidermal growth factor receptor in rat-2 cells. IUBMB Life. 50: 119-124.
40. Endo, A., K. Nagashima, H. Kurose, S. Mochizuki, M. Matsuda, and N. Mochizuki. 2002. Sphingosine 1-phosphate induces membrane ruffling and increases motility of human umbilical vein endothelial cells via vascular endothelial growth factor receptor and CrkII. J. Biol. Chem. 277: 23747-23754.
41. Tanimoto, T., Z. G. Jin, and B. C. Berk. 2002. Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J. Biol. Chem. 277: 42997-43001.
42. Rani, C. S., F. Wang, E. Fuior, A. Berger, J. Wu, T. W. Sturgill, D. Beitner-Johnson, D. LeRoith, L. Varticovski, and S. Spiegel. 1997. Divergence in signal transduction pathways of platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) receptors. Involvement of sphingosine 1-phosphate in PDGF but not EGF signaling. J. Biol. Chem. 272: 10777-10783.
43. Marti, H. P., L. Lee, M. Kashgarian, and D. H. Lovett. 1994. Transforming growth factor-beta 1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase. Am. J. Pathol. 144: 82-94.
44. Akool, el-S., A. Doller, R. Müller, P. Gutwein, C. Xin, A. Huwiler, J. Pfeilschifter, and W. Eberhardt. 2005. Nitric oxide induces TIMP-1 expression by activating the transforming growth factor β-Smad signaling pathway. J. Biol. Chem. 280: 39403-39416.
45. Gerwin, B. I., J. Keski-Oja, M. Seddon, J. F. Lechner, and C. C. Harris. 1990. TGF-β1 modulation of urokinase and PAI-1 expression in human bronchial epithelial cells. Am. J. Physiol. 259: L262-L269.
46. Ogawa, K., F. Chen, C. Kuang, and Y. Chen. 2004. Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappaB site. Biochem. J. 381: 413-422.
47. Yagi, K., M. Furuhashi, H. Aoki, D. Goto, H. Kuwano, K. Sugamura, K. Miyazono, and M. Kato. 2002. c-myc is a downstream target of the Smad pathway. J. Biol. Chem. 277: 854-861.
48. Frederick, J. P., N. T. Liberati, D. S. Waddell, Y. Shi, and X. F. Wang. 2004. Transforming growth factor β-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol. Cell. Biol. 24: 2546-2559.
49. Hallatschek, W., G. Fiedler, C. J. Kirschning, F. Creutzburg, N. Lamping, A. Nussler, and R. R. Schumann. 2004. Inhibition of hepatic transcriptional induction of lipopolysaccharide-binding protein by transforming-growth-factor β1. Eur. J. Immunol. 34: 1441-1450.
50. Li, H., D. Xu, J. Li, M. C. Berndt, and J. P. Liu. 2006. Transforming growth factor β suppresses human telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene. J. Biol. Chem. 281: 25588-25600.
51. Li, C., N. L. Zhu, R. C. Tan, P. L. Ballard, R. Derynck, and P. Minoo. 2002. Transforming growth factor-β inhibits pulmonary surfactant protein B gene transcription through SMAD3 interactions with NKX2.1 and HNF-3 transcription factors. J. Biol. Chem. 277: 38399-38408.
52. Mogami, K., Y. Mizukami, N. Todoroki-Ikeda, M. Ohmura, K. Yoshida, S. Miwa, M. Matsuzaki, M. Matuda, and S. Kobayashi. 1999. Sphingosylphosphorylcholine induces cytosolic Ca(2+) elevation in endothelial cells in situ and causes endothelium-dependent relaxation through nitric oxide production in bovine coronary artery. FEBS Lett. 457: 375-380.
53. Todoroki-Ikeda, N., Y. Mizukami, K. Mogami, T. Kusuda, K. Yamamoto, T. Miyake, M. Sato, S. Suzuki, H. Yamagata, Y. Hokazono, et al. 2000. Sphingosylphosphorylcholine induces Ca(2+)-sensitization of vascular smooth muscle contraction: possible involvement of rho-kinase. FEBS Lett. 482: 85-90.
54. Nofer, J. R., and G. Assmann. 2005. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc. Med. 15: 265-271.
55. Schmidt, A., S. Geigenmuller, W. Volker, and E. Buddecke. 2006. The antiatherogenic and antiinflammatory effect of HDL-associated lysosphingolipids operates via Akt→NF-κB signalling pathways in human vascular endothelial cells. Basic Res. Cardiol. 101: 109-116.
56. Liliom, K., G. Sun, M. Bunemann, T. Virag, N. Nusser, D. L. Baker, D. A. Wang, M. J. Fabian, B. Brandts, K. Bender, et al. 2001. Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem. J. 355: 189-197.
57. 31P nuclear magnetic resonance spectroscopy. Lipids. 29: 359-364.
58. Beil, M., A. Micoulet, G. von Wichert, S. Paschke, P. Walther, M. B. Omary, P. P. van Veldhoven, U. Gern, E. Wolff-Hieber, J. Eggermann, et al. 2003. Sphingosylphosphorylcholine regulates keratin network architecture and visco-elastic properties of human cancer cells. Nat. Cell Biol. 5: 803-811.
59. Kleger, A., T. Busch, S. Liebau, K. Prelle, S. Paschke, M. Beil, A. Rolletschek, A. Wobus, E. Wolf, G. Adler, et al. 2007. The bioactive lipid sphingosylphosphorylcholine induces differentiation of mouse embryonic stem cells and human promyelocytic leukaemia cells. Cell. Signal. 19: 367-377.
60. Hara, J., K. Higuchi, R. Okamoto, M. Kawashima, and G. Imokawa. 2000. High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J. Invest. Dermatol. 115: 406-413.
61. Higuchi, K., J. Hara, R. Okamoto, M. Kawashima, and G. Imokawa. 2000. The skin of atopic dermatitis patients contains a novel enzyme, glucosylceramide sphingomyelin deacylase, which cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. Biochem. J. 350: 747-756.
62. Murata, Y., J. Ogata, Y. Higaki, M. Kawashima, Y. Yada, K. Higuchi, T. Tsuchiya, S. Kawainami, and G. Imokawa. 1996. Abnormal expression of sphingomyelin acylase in atopic dermatitis: an etiologic factor for ceramide deficiency? J. Invest. Dermatol. 106: 1242-1249.
63. Imokawa, G., Y. Takagi, K. Higuchi, H. Kondo, and Y. Yada. 1999. Sphingosylphosphorylcholine is a potent inducer of intercellular adhesion molecule-1 expression in human keratinocytes. J. Invest. Dermatol. 112: 91-96.
64. Berger, A., D. Rosenthal, and S. Spiegel. 1995. Sphingosylphosphocholine, a signaling molecule which accumulates in Niemann-Pick disease type A, stimulates DNA-binding activity of the transcription activator protein AP-1. Proc. Natl. Acad. Sci. USA. 92: 5885-5889.
65. Hostetler, K. Y., P. J. Yazaki, and H. van den Bosch. 1982. Purification of lysosomal phospholipase A. Evidence for multiple isoenzymes in rat liver. J. Biol. Chem. 257: 13367-13373.
66. Hiraoka, M., A. Abe, and J. A. Shayman. 2002. Cloning and characterization of a lysosomal phospholipase A2, 1-O-acylceramide synthase. J. Biol. Chem. 277: 10090-10099.
67. Umezu-Goto, M., Y. Kishi, A. Taira, K. Hama, N. Dohmae, K. Takio, T. Yamori, G. B. Mills, K. Inoue, J. Aoki, et al. 2002. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158: 227-233.
68. Clair, T., J. Aoki, E. Koh, R. W. Bandle, S. W. Nam, M. M. Ptaszynska, G. B. Mills, E. Schiffmann, L. A. Liotta, and M. L. Stracke. 2003. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res. 63: 5446-5453.
69. Van Meeteren, L. A., P. Ruurs, C. Stortelers, P. Bouwman, M. A. van Rooijen, J. P. Pradere, T. R. Pettit, M. J. Wakelam, J. S. Saulnier-Blache, C. L. Mummery, et al. 2006. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell. Biol. 26: 5015-5022.